ProFound AI Risk Real-World Case Studies to be featured in iCAD’s “ProFound Insights, ProFound Impact” Webinar Series
June 29, 2022
Leading radiologists to highlight
clinical examples demonstrating power of iCAD’s complete suite of ProFound AI
Breast Health Solutions
NASHUA, N.H. – June 29, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that leading
radiologists will highlight clinical examples demonstrating the power of ProFound AI® Ris... Continue reading
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Highlight ProFound AI Risk
June 07, 2022
Leading experts, including distinguished
researchers from the Karolinska Institutet and clinicians using it in daily
practice, to discuss significant impact and value of technology
NASHUA, N.H. – June 7, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that its
next webinar, titled “Risk Assessm... Continue reading
iCAD Announces CFO Transition
May 25, 2022
Stephen P. Sarno appointed as interim
Chief Financial Officer to the Company, effective immediately
NASHUA,
N.H., May 25, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced the Board of
Directors has approved the appointment of Stephen P. Sarno as interim Chief
Financial Officer (CFO), effective immediately. Mr. Sarno will assist with the
transition as Charles Carter departs the Company this month.
Continue reading
New Real-World Evidence Shows ProFound AI Improves Cancer Detection and Accuracy with Digital Breast Tomosynthesis, or 3D Mammography
May 18, 2022
Research presented at the 2022
SBI/ACR Breast Imaging Symposium confirms ProFound AI significantly enhances
radiologists’ screening performance
NASHUA,
N.H., May 18, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that new
research supporting ProFound AI® for Digital Breast Tomosynthesis (DBT) will be presented at the Society
of Breast Imaging (SBI/ACR) Breast Imaging Symposium, taking place May 16-19 in
Sava... Continue reading
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
May 17, 2022
Using U.S. guidelines, ProFound AI Risk found
14% of women studied who had a negative screen had
almost 20 times higher risk of developing breast cancer in the next year than
the general risk population
iCAD recently announced that promising clinical
research supporting ProFound AI® Risk for Digital Breast Tomosynthesis (DBT) – the world’s first clinical
decision support tool that provides an accurate short-term breast cancer risk
estimation based on age, breast density and mammographic fea... Continue reading
New Research Finds iCAD's ProFound AI Risk for Digital Breast Tomosynthesis is 2.4x More Accurate than Traditional Lifetime Risk Models
May 16, 2022
Using U.S. guidelines, ProFound AI Risk found 14% of women studied who had a negative screen had almost 20 times higher risk of developing breast cancer in the next year than the general risk population
NASHUA, N.H., May 16, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that promising clinical research supporting ProFou... Continue reading
iCAD to Present at the Spring Into Action – Best Ideas Virtual Investor Conference on May 17th, 2022
May 12, 2022
NASHUA,
N.H., May 12, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced the Company
will present at the Spring Into Action – Best Ideas Virtual Investor
Conference, which is being held virtually on May 16th – 20th, 2022.
Stacey Stevens, President and CEO of iCAD, Inc. will pre... Continue reading
iCAD Reports Financial Results for First Quarter Ended March 31, 2022
May 11, 2022
Company to host
conference call and webcast today at 4:30 PM ET
NASHUA, N.H. – May
11, 2022 – iCAD, Inc.
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today reported its
financial and operating results for the three months ended March 31, 2022.
Highlights:
Commercial reorganization shows early success
leading to a ProFound AI® enterprise agreement at a world-renowned
academic research...
Continue reading
iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Clinical and IT Experts from Wake Radiology
April 28, 2022
Leading healthcare provider with 14 imaging
centers in North Carolina identified ProFound AI as the premier solution in a competitive
trial based on unique workflow benefits and multivendor flexibility
NASHUA, N.H. – April 28, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that the
next event in its “ProFound Insights, ProFound Impact” webinar series w... Continue reading
iCAD to Report First Quarter 2022 Financial Results on Wednesday, May 11
April 27, 2022
NASHUA,
N.H. – April 27, 2022 – iCAD®, Inc. (NASDAQ:
ICAD), a global medical technology leader providing innovative cancer
detection and therapy solutions, today announced that it will release
financial results for the first quarter ended March 31, 2022, after the market
close, and host a conference call at 4:30 PM Eastern Time on Wednesday, May 11.
Wednesday, May 11th at 4:30 PM ET
Domestic: 888-506-0062
Continue reading
iCAD Announces Significant Commercial Momentum for ProFound AI® Among Customers Equipped with the Leading Provider of 3D Mammography Systems
April 26, 2022
Customers report continued workflow advantages and clinical
superiority with iCAD’s suite of AI‐powered breast health solutions, compared
to other available breast AI solutions
NASHUA,
N.H. – April 26, 2022 ‐ iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
announced significant commercial momentum for ProFound AI®,
driving attachment to the leading provider of 3D... Continue reading
iCAD Announces Estimated Q1 Revenue and Upcoming Board and CFO Transitions
April 21, 2022
Company expects preliminary estimated
revenue to be .5 million
Timothy Norris Irish Appointed
Chairman of the Board of Directors, Successor CFO search underway
NASHUA, N.H. – April 21, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader pro... Continue reading
iCAD Launches ProFound Insights, ProFound Impact Webinar Series on April 27
April 19, 2022
First event to feature Kettering
Health, a leading enterprise breast care provider with 14 breast centers across
southwest Ohio
NASHUA, N.H. – April 19, 2022 - iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced that it will
launch a new webinar series, ProFound Insights, ProFound Impact, which will highl... Continue reading
iCAD Announces Additional Patients Treated Under GLIOX Trial and Continued Global Momentum for Xoft Intraoperative Radiation Therapy (IORT) for Brain, Rectal, Head and Neck Tumor Treatment
April 05, 2022
Multiple leading institutions leverage the versatility
of Xoft electronic brachytherapy (eBx) to increasingly treat multiple cancers
NASHUA, N.H. – April 5, 2021 – iCAD, Inc. (NASDAQ: ICAD), a
global medical technology leader providing innovative cancer detection and
therapy solutions, today announced that additional patients have been treated
under the international multi-center GLIOX trial and customers globally are
continui... Continue reading
Why ProFound AI Prevailed as the Premier AI Solution in a Competitive Trial at Wake Radiology
April 04, 2022
With 14 imaging locations in the Raleigh-Durham metropolitan
area, also known as “the Triangle,” Wake Radiology offers a wide array of
imaging exams in the outpatient setting, including both screening and
diagnostic mammography. Renowned for state-of-the-art care, in August 2013 Wake
Radiology began to upgrade to 3D mammography, or DBT, and now exclusively
offers DBT at all 14 locations, all of which are designated as American College
of Radiology Breast Imaging Centers of Excellence (BICOE).
“We pride o... Continue reading
Why Kettering Health Traded out Previous AI Software for ProFound AI® Enterprise-Wide
March 15, 2022
The Story of Kettering Health
A leading faith based, not-for-profit hospital system in
southwest Ohio, Kettering Health has been providing quality
patient care and cancer screening at its world-class cancer centers for 48
years. The team at Kettering takes great pride in ensuring that its facilities
are equipped with the latest in state-of-the-art technology that empowers their
team to provide the best possible patient care.
“... Continue reading
iCAD Highlights Breast Health AI Platform at the 2022 Healthcare Information and Management Systems Society (HIMSS) Meeting
March 14, 2022
World-leading breast cancer AI
solutions featured for demonstration in iCAD booth
NASHUA,
N.H., March 14, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced it will be showcasing its portfolio of Breast AI solutions, including ProFound
AI® for Digital Breast Tomosynthesis (DBT) in the iCAD booth (#4000) at the 2022 Healthcare Information and
Management Sys... Continue reading
iCAD Showcases Innovative Breast Health Solutions Platform at National Consortium of Breast Centers (NCoBC) 31st Annual Conference
March 10, 2022
iCAD’s
award winning portfolio of breast health solutions to be featured at inaugural
Pink Paradigm Summit, uniting clinical and advocacy leadership
NASHUA,
N.H., March 10, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing
innovative cancer detection and therapy solutions, today announced it will be showcasing its portfolio of innovative
breast health solutions at the National Consortium of Breast Centers (NCoBC)
Annual Confere... Continue reading
iCAD to Present at the 32nd Annual Oppenheimer Healthcare Conference
March 09, 2022
NASHUA, N.H., March 9, 2022 -- iCAD, Inc. (NASDAQ: ICAD), a
global medical technology leader providing innovative cancer detection and
therapy solutions, today announced the Company will participate in the virtual 32nd
Annual Oppenheimer Healthcare Conference, taking place March 15-17, 2022.
Stacey Stevens, President and CEO of iCAD, Inc. is
scheduled to present on Thursday, March 17, 2022, at 8:00 a.m. EST. The
webcast of this event can be vi... Continue reading
iCAD Among the First to Validate its AI Cancer Detection Solutions with the NVIDIA AI Enterprise Software Suite
March 02, 2022
NVIDIA platform streamlines adoption,
accelerates deployment of iCAD’s solutions in virtualized data centers
NASHUA, N.H. – March 2, 2022 – iCAD, Inc. (NASDAQ: ICAD), a global medical
technology leader providing innovative cancer detection and therapy solutions,
today announced that it is among the first to validate its AI solutions with
the NVIDIA® AI
Ente... Continue reading
100 Comments